Terns Pharmaceuticals, Inc. (TERN)
|52 Week Range||4.38-14.044|
|1y Target Est||-|
|DCF Unlevered||TERN DCF ->|
|DCF Levered||TERN LDCF ->|
|Debt / Equity||0.32%||Neutral|
Upgrades & Downgrades
Latest TERN news
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
28 July 2023
Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will d...
Terns Pharmaceuticals: Facing Impressive Competition, But Not Completely Out Of Its Depth
20 July 2023
TERN's TERN-701 is being developed for Chronic Myeloid Leukemia (CML), but NVS' Scemblix is similar and already approved. TERN-701 may offer benefits to Scemblix, some of which could become apparent a...
Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
6 June 2023
FOSTER CITY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small...
Terns Pharmaceuticals: Upcoming Obesity Data Is One Of Many Catalysts Coming Up
1 June 2023
Terns Pharmaceuticals has a promising pipeline with potential best-in-class therapies for obesity and NASH. Upcoming data readouts for TERN-601 and TERN-501 could unlock value, with positive outcomes ...
Terns Pharmaceuticals to Present at Upcoming Investor Conferences
24 May 2023
FOSTER CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know
25 April 2023
Does Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Shares of Terns Pharmaceuticals Soared This Week
30 March 2023
Terns Pharmaceuticals released fourth-quarter and full-year earnings on Monday. The company is looking at therapies to treat various oncology targets, obesity, and non-alcoholic steatohepatitis (NASH)...
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
29 March 2023
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient po...
Terns Pharmaceuticals: Early-Stage Biopharma Worthy Of Your Attention
21 March 2023
TERN has a growing pipeline of early-stage assets against validated targets. TERN's internal discovery team has been productive at developing small molecules against key targets in big markets.